Clinical Trial Update: Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of Fruquintinib plus FOLFIRI in patients with RAS-mutated metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: UNKNOWN